WO2022202214A1 - FormII型の還元型補酵素Q10結晶又はその結晶性固体の製造方法 - Google Patents
FormII型の還元型補酵素Q10結晶又はその結晶性固体の製造方法 Download PDFInfo
- Publication number
- WO2022202214A1 WO2022202214A1 PCT/JP2022/009361 JP2022009361W WO2022202214A1 WO 2022202214 A1 WO2022202214 A1 WO 2022202214A1 JP 2022009361 W JP2022009361 W JP 2022009361W WO 2022202214 A1 WO2022202214 A1 WO 2022202214A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- reduced coenzyme
- ftu
- crystals
- alcohol
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
- C07C50/28—Quinones containing groups having oxygen atoms singly bound to carbon atoms with monocyclic quinoid structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C46/00—Preparation of quinones
- C07C46/10—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
- C07C41/01—Preparation of ethers
- C07C41/34—Separation; Purification; Stabilisation; Use of additives
- C07C41/40—Separation; Purification; Stabilisation; Use of additives by change of physical state, e.g. by crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- the present disclosure relates to a method for producing Form II reduced coenzyme Q10 crystals or a crystalline solid thereof.
- Coenzyme Q is an essential component that is widely distributed in living organisms, from bacteria to mammals, and is known as a component of the mitochondrial electron transport system in cells in living organisms. Coenzyme Q repeats oxidation and reduction in mitochondria, thereby serving as a transfer component in the electron transport system, and reduced coenzyme Q is known to have an antioxidant effect.
- coenzyme Q10 which has 10 repeating structures in the side chain of coenzyme Q, is the main component, and about 40 to 90% of the coenzyme exists in vivo as a reduced form.
- Physiological actions of coenzyme Q include activation of energy production by mitochondrial activation, activation of cardiac function, stabilization of cell membranes, and protection of cells by antioxidant action.
- Patent Document 1 A general method for obtaining reduced coenzyme Q10 has already been disclosed (Patent Document 1). Furthermore, several methods are known for obtaining reduced coenzyme Q10 as crystals. For example, a method of crystallizing reduced coenzyme Q10 in an alcohol solution and/or a ketone solution to produce crystals (Patent Document 2), or adding a high-concentration liquid phase of reduced coenzyme Q10 to a poor solvent. A method (Patent Document 3) for crystallization by crystallization has been reported.
- Patent Document 4 describes that crystal polymorphism is observed in reduced coenzyme Q10. Or called Form II type crystal) is much more stable than conventional reduced coenzyme Q10 (hereinafter, this crystal is called Form I type reduced coenzyme Q10 crystal, or Form I type crystal), and other It is also reported to have excellent physical properties.
- Patent Document 5 describes a method for producing Form II-type reduced coenzyme Q10 crystals.
- at least one organic solvent selected from the group consisting of alcohols, hydrocarbons, fatty acid esters and nitrogen compounds, and reduced coenzyme Q10 are contained, and the temperature is 32 to 43 C.
- a method for producing Form II reduced coenzyme Q10 crystals comprising:
- Patent Document 4 describes a method of crystallization under specific conditions as a method for obtaining Form II reduced coenzyme Q10 crystals. This method is not necessarily industrially optimal.
- the method disclosed in Patent Document 5 aims to provide an efficient production method suitable for industrial-scale production for obtaining Form II reduced coenzyme Q10 crystals. A method focused primarily on temperature is disclosed.
- Form II reduced coenzyme Q10 crystals are conventionally obtained by solid-liquid separation by means of filtration or the like after obtaining a slurry containing Form II reduced coenzyme Q10 crystals, followed by appropriate drying or other steps.
- the present inventors found that when filtering a slurry containing Form II reduced coenzyme Q10 crystals, if the filterability of the slurry is poor, it is necessary to frequently wash or replace the filtering device. I thought it would be
- an object of the present disclosure is to provide a method for producing Form II reduced coenzyme Q10 crystals or a crystalline solid thereof, which is excellent in filterability of slurry containing Form II reduced coenzyme Q10 crystals.
- Form II reduced coenzyme Q10 crystals When forming Form II reduced coenzyme Q10 crystals in a mixed solution containing alcohol and reduced coenzyme Q10, as the precipitation progresses, Form II reduced coenzyme Q10 crystals in the mixed solution increase. Turbidity increases due to increase. The present inventors have found that a slurry containing Form II reduced coenzyme Q10 crystals has excellent filterability by controlling the rate of change in turbidity.
- Example aspects of this embodiment are described as follows. (1) adding FormII-type reduced coenzyme Q10 crystals as seed crystals to a mixture containing alcohol and reduced coenzyme Q10; In the precipitation, the FTU change rate is 15 FTU for 80% or more of the period from 1,000 to 10,000 for the formazin turbidity (FTU) A method for producing FormII-type reduced coenzyme Q10 crystals or a crystalline solid thereof, which is maintained at a temperature of at least /min. (2) The production method according to (1), wherein the Form II reduced coenzyme Q10 crystals to be produced have a median diameter (D50) of 80 ⁇ m or more.
- D50 median diameter
- the FTU change rate is maintained at 110 FTU / min or less for 80% or more of the period from 1,000 to 10,000 in formazin turbidity (FTU), (1) or ( 2) The manufacturing method as described in.
- the production method according to (5), wherein the monohydric alcohol having 1 to 5 carbon atoms is ethanol.
- This specification includes the disclosure content of Japanese Patent Application No. 2021-052652, which is the basis of priority of this application.
- the method of the present disclosure is excellent in filterability of slurry containing Form II reduced coenzyme Q10 crystals.
- reduced coenzyme Q10 may partially contain oxidized coenzyme Q10 as long as it contains reduced coenzyme Q10 as a main component.
- the main component is, for example, 50% by weight or more, usually 60% by weight or more, preferably 70% by weight or more, more preferably 80% by weight or more, still more preferably 90% by weight or more, particularly preferably 95% by weight. More preferably, it means that the content is 98% by weight or more.
- the ratio is the ratio of reduced coenzyme Q10 to the total amount of coenzyme Q10.
- reduced coenzyme Q10 has two types of crystal polymorphs: the conventionally known Form I type and the recently discovered Form II type. Specifically, the melting point is around 48° C., and the diffraction angles (2 ⁇ 0.2°) are 3.1°, 18.7°, 19.0°, and 20° in powder X-ray (Cu—K ⁇ ) diffraction.
- the crystal form of reduced coenzyme Q10 showing characteristic peaks at 2° and 23.0° is Form I type, and has a melting point of around 52°C. ⁇ 0.2°) Crystal form of reduced coenzyme Q10 showing characteristic peaks at 11.5°, 18.2°, 19.3°, 22.3°, 23.0°, and 33.3° is Form II type.
- DSC differential scanning calorimetry
- Crystal solid as used herein means a solid containing therein a portion having a crystalline structure and an amorphous component having no crystalline structure. That is, the "crystalline solid thereof” in "Form II reduced coenzyme Q10 crystal or crystalline solid thereof” means “a portion having a crystal structure of a Form II reduced coenzyme Q10 crystal and having a crystal structure. means "a solid that contains no amorphous component therein”.
- the alcohol is preferably a monohydric alcohol having 1 to 5 carbon atoms.
- monohydric alcohols having 1 to 5 carbon atoms include methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol and n-pentanol.
- ethanol is particularly preferred because the saturation concentration of Form II crystals is sufficiently lower than the saturation concentration of Form I crystals and is easy to handle.
- alcohol what was illustrated above may be used individually, and 2 or more types may be mixed and used.
- the alcohol in the present specification may be a solvent containing alcohol as a main component, and may be a hydrous alcohol containing water.
- alcohol has an alcohol concentration of, for example, 80% by weight or more, usually 90% by weight or more, preferably 95% by weight or more, more preferably 97% by weight or more, and still more preferably 99% by weight, based on the total amount of water and alcohol. It is at least 99.5% by weight, particularly preferably at least 99.5% by weight.
- Alcohol having an alcohol concentration of 99.5% by weight or more means anhydrous alcohol.
- the upper limit of the alcohol concentration is 100% by weight or less.
- Ethanol has an ethanol concentration of, for example, 80% by weight or more, usually 90% by weight or more, preferably 95% by weight or more, more preferably 97% by weight or more, and still more preferably 99% by weight, based on the total amount of water and ethanol. It is at least 99.5% by weight, particularly preferably at least 99.5% by weight. Moreover, the upper limit of the ethanol concentration is 100% by weight or less.
- Form II reduced coenzyme Q10 crystals or crystalline solids thereof are added to a mixed solution containing alcohol and reduced coenzyme Q10. adding as seed crystals, and precipitating FormII-type reduced coenzyme Q10 crystals in the mixed solution after adding the seed crystals, wherein the precipitation has a formazin turbidity (FTU) of 1,
- FTU formazin turbidity
- the step of adding Form II reduced coenzyme Q10 crystals as seed crystals is referred to as the "seeding step”
- the step of precipitating Form II reduced coenzyme Q10 crystals is referred to as the “crystal precipitation step”.
- the mixed solution containing alcohol and reduced coenzyme Q10 is not particularly limited as long as it contains alcohol and reduced coenzyme Q10.
- it may be a slurry in which reduced coenzyme Q10 is partly dissolved in alcohol but partly not dissolved but suspended in alcohol.
- reduced coenzyme Q10 is dissolved in alcohol. Homogeneous solution.
- the reduced coenzyme Q10 used in the mixture containing alcohol and reduced coenzyme Q10 may be in a crystalline or amorphous state, and its crystal polymorphism may be used. Therefore, conventionally known Form I reduced coenzyme Q10 can also be used. In addition, since it is possible to increase the purity by crystal precipitation, it may be an unpurified or partially purified reduced coenzyme Q10 containing impurities. Furthermore, an extract of reduced coenzyme Q10 obtained by a conventionally known method or a reaction solution containing reduced coenzyme Q10 obtained from oxidized coenzyme Q10 by a known reduction method may be used as it is or as necessary. Purified and/or solvent-substituted one can also be used as the mixed solution.
- the mixed solution containing alcohol and reduced coenzyme Q10 may further contain organic solvents other than alcohol (including hydrous alcohol), but the alcohol content (alcohol purity ) is preferably 95% by weight or more, 97% by weight or more, or 99% by weight or more, and the upper limit is preferably 100% by weight or less. The alcohol purity is most preferably 99.5% by weight or higher.
- organic solvents include at least one selected from the group consisting of hydrocarbons, fatty acid esters and nitrogen compounds.
- the dissolved concentration of reduced coenzyme Q10 before addition of seed crystals in the mixed solution containing alcohol and reduced coenzyme Q10 is, for example, 2% by weight or more, preferably 3% by weight or more, and more preferably 5% by weight. Above, more preferably 7% by weight or more, particularly preferably 9% by weight or more.
- the dissolved concentration of reduced coenzyme Q10 before addition of seed crystals is, for example, 50% by weight or less, preferably 45% by weight or less, more preferably 30% by weight or less, even more preferably 20% by weight or less, and particularly preferably 15% by weight. It is below.
- a mixed solution containing alcohol and reduced coenzyme Q10 is prepared by heating a raw material mixture containing alcohol and reduced coenzyme Q10 to a temperature of, for example, 42° C. or higher to dissolve reduced coenzyme Q10. can get.
- the temperature is preferably 70° C. or lower, more preferably 55° C. or lower.
- the mixture containing the alcohol and the reduced coenzyme Q10 is preferably cooled to the temperature at which the seed crystals are added, which will be described later. .
- the amount of Form II-type reduced coenzyme Q10 crystals to be added (the amount of seed crystals to be added) is not particularly limited, but the amount of reduced coenzyme Q10 (100 % by weight), preferably 0.1% by weight or more, more preferably 0.5% by weight or more, even more preferably 0.8% by weight or more, and particularly preferably 1% by weight or more.
- the upper limit is not particularly limited, it is preferably 20% by weight or less, more preferably 4% by weight or less, relative to the amount (100% by weight) of reduced coenzyme Q10 in the mixed solution before adding seed crystals. 2% by weight or less is more preferable.
- the reduced coenzyme Q10 crystals used as seed crystals may contain Form I reduced coenzyme Q10 crystals or amorphous forms, as long as they contain Form II reduced coenzyme Q10 crystals. However, it is preferable that the purity of Form II reduced coenzyme Q10 crystals is high.
- Form II reduced coenzyme Q10 crystals for example, 50% by weight or more, preferably 75% by weight or more, more preferably 80% by weight or more, more preferably 90% by weight or more, are used as seed crystals. good.
- the temperature of the mixed liquid at the time of adding the seed crystals is preferably 30 to 43°C.
- the temperature of the mixed solution at the time of adding the seed crystals is more preferably 32° C. or higher, particularly preferably 34° C. or higher, and more preferably 40° C. or lower. Within this range, selective precipitation of Form II reduced coenzyme Q10 crystals is easy.
- the crystal precipitation step includes maintaining the FTU change rate at 15 FTU/min or more for 80% or more of the period until the formazin turbidity (FTU) becomes 1,000 to 10,000.
- the FTU change rate is preferably 16 FTU/min or more, more preferably 18 FTU/min or more, and even more preferably 20 FTU/min or more.
- FTU increases as crystal precipitation progresses, but by maintaining the FTU change rate in the above range for 80% or more of the period from FTU to 1,000 to 10,000, Form II reduced form Excellent filterability of slurry containing coenzyme Q10 crystals.
- the reason for this is that the present inventors believe that an increase in FTU means that crystal precipitation is progressing, and that by setting the FTU change rate to a specific range, the formation of crystals with a small median diameter due to gentle precipitation can be suppressed. It was presumed that it was possible to suppress it.
- the FTU rate of change falls outside the specified range for a portion of the period from 1,000 to 10,000 FTU, the period from 1,000 to 10,000 FTU
- Form II reduced coenzyme Q10 crystals with excellent filterability can be stably produced if the FTU change rate is within the above specific range for 80% or more of the time.
- the time of 80% or more of the period until the FTU increases from 1,000 to 10,000 means, for example, if it takes 300 minutes to increase the FTU from 1,000 to 10,000, 240 minutes If it means 900 minutes or more, it means 720 minutes or more.
- the reduced coenzyme Q10 is uniformly dissolved in alcohol in the mixed solution at the time of adding the seed crystals.
- the FTU of the mixed liquid at the time of seed crystal addition is usually 0-250, preferably 0-230, more preferably 0-200. This range is preferable because Form II reduced coenzyme Q10 crystals preferentially precipitate.
- the FTU change rate at a certain time (T) can be calculated by the following formula.
- FTU change rate T (FTU/min) (measured turbidity value T (FTU) - measured turbidity value T-20 (FTU))/20 (min)
- the FTU change rate T means the FTU change rate at time (T)
- the turbidity measurement value T (FTU) means the FTU measurement value at time (T)
- the turbidity measurement value T- 20 (FTU) means the FTU measurement 20 minutes before time T.
- the FTU change rate can be calculated by measuring the FTU every 20 minutes and dividing the increase in FTU during that period by 20 minutes. That is, in a certain aspect, even if the FTU change rate is outside the range of this embodiment for a very short time (for example, 1 minute), when the FTU is measured every 20 minutes, the FTU change rate is When within the scope of the embodiment, the aspect assumes that the FTU rate of change satisfies the requirements of the embodiment.
- Formazin turbidity is preferably maintained at 110 FTU / min or less for 80% or more of the period from 1,000 to 10,000, more preferably 90 FTU / min or less. It is preferably 60 FTU/min or less, and more preferably 60 FTU/min or less.
- the FTU change rate is set to the FTU change rate for the entire period (100% of the time) from 1,000 to 10,000, the above-mentioned specific range, for example, the FTU change rate is 15 FTU / min or more, preferably It is one of the preferable aspects to maintain at 20 FTU/min or more.
- the FTU change rate is 110 FTU / min or less, preferably 85 FTU / min or less, more preferably 60 FTU / min or less for the entire period (100% of the time) until the FTU becomes 1,000 to 10,000 Maintaining is also one of the preferable aspects.
- the temperature of the mixed solution is preferably 30° C. or higher and 43° C. or lower, and preferably 30.5° C. or higher and 42° C. or lower during the period until the formazin turbidity (FTU) becomes 1,000 to 10,000. It is more preferably 31° C. or higher and 41° C. or lower, particularly preferably. Within the above range, it is easy to maintain the FTU change rate within the above range, which is preferable.
- the temperature of the mixture is preferably 29° C. or higher and 38° C. or lower, more preferably 30° C. or higher and 37° C. or lower, and 31° C. or higher and 36° C. or lower. Especially preferred.
- the temperature of the mixed solution can be adjusted as appropriate according to the formazin turbidity and FTU change rate at that time.
- the temperature of the mixed liquid may be constant, but may be lowered stepwise or continuously.
- the temperature of the mixture may be maintained at a constant temperature for a certain period of time and then lowered stepwise or continuously.
- the temperature of the mixture at the time of adding the seed crystals is 34° C. or more and 38° C. or less
- the temperature of the mixture at the time when the FTU is 10,000 is 30° C. or more and 37° C. or less.
- the temperature at which the FTU is 10,000 is preferably 0.4° C. or more and 8° C.
- the term "maintained at a constant temperature” means preferably to maintain a predetermined temperature (set temperature) ⁇ 3°C, more preferably to maintain a predetermined temperature (set temperature) ⁇ 1°C.
- the cooling rate when lowering the temperature of the mixture is preferably 0.05°C/hr or more and 20°C/hr or less, more preferably 0.1°C/hr or more and 15°C/hr or less. It is also a preferred embodiment to change the cooling rate over time.
- the temperature is maintained for a certain period of time, for example, 0.5 to 8 hours, and the cooling rate is set to 0.05° C./hr or more and less than 0.5° C./hr for 3 to 20 hours thereafter, After that, the cooling rate is set to 0.5° C./hr or more and 15° C./hr or less, and after adding the seed crystal, the cooling rate is set to 0.05° C./hr or more and less than 0.5° C./hr for 3 to 20 hours. After that, the cooling rate is set to 0.5° C./hr or more and 15° C./hr or less.
- the temperature of the mixed solution it is preferable to lower the temperature of the mixed solution and precipitate crystals even after the formazin turbidity reaches 10,000.
- the cooling rate at that time can be set, for example, based on the range described above.
- the temperature of the mixed solution reaches 23 to 34°C, most of the reduced coenzyme Q10 contained in the mixed solution has already precipitated, so after the temperature reaches 23 to 34°C, For example, it is possible to increase the cooling rate from 1° C./hr to 20° C./hr.
- the temperature at the time of finishing the crystal precipitation step is preferably 25°C or less, more preferably 20°C or less, more preferably 10°C or less, more preferably 7°C or less, more preferably 5°C or less. is.
- the lower limit of the end point temperature is the solidification temperature of the mixed liquid system, and is preferably 0° C. or higher.
- Precipitation of crystals is preferably carried out while forcibly flowing the liquid mixture.
- the power required for stirring per unit volume is usually 0.003 kW/m 3 or more, preferably 0.004 kW. /m 3 or more, more preferably 0.005 kW/m 3 or more, more preferably 0.006 kW/m 3 or more, to the mixture.
- the above-mentioned forced flow is usually provided by rotating a stirring blade, but if the above-mentioned flow is obtained, it is not always necessary to use a stirring blade, and for example, a method of circulating the mixed liquid may be used.
- a mixed solution (slurry) in which Form II reduced coenzyme Q10 crystals are precipitated is obtained. Since the method according to the present embodiment has excellent filterability of the slurry, Form II reduced coenzyme Q10 crystals can be easily recovered from the slurry by filtration.
- the Form II reduced coenzyme Q10 crystals obtained by the above method are recovered from the slurry through solid-liquid separation and drying steps by conventionally known methods such as those described in Patent Documents 2 and 3, for example. .
- pressure filtration, centrifugal filtration, or the like can be used for solid-liquid separation.
- the dried crystals and crystalline solids can be recovered by pulverizing and classifying (sieving) as necessary.
- the median diameter (D50) of Form II reduced coenzyme Q10 crystals obtained by the above method is preferably 80 ⁇ m or more, more preferably 83 ⁇ m or more, and particularly preferably 85 ⁇ m or more.
- the median diameter (D50) of Form II reduced coenzyme Q10 crystals is preferably 130 ⁇ m or less, more preferably 125 ⁇ m or less, and particularly preferably 120 ⁇ m or less. It is preferable that the median diameter (D50) is within the Senki range, since the slurry containing Form II reduced coenzyme Q10 crystals has excellent filterability.
- the Form II reduced coenzyme Q10 crystals after the solid-liquid separation are dried under heating to obtain Form II reduced coenzyme Q10 crystals. It is also possible to improve the content ratio.
- the drying temperature is preferably 46° C. or higher, more preferably 47° C. or higher, and even more preferably 49° C. or higher.
- the upper limit is usually 52°C or lower, preferably 51°C or lower. If the temperature is less than 46° C., drying progresses, but the content of Form II-type reduced coenzyme Q10 crystals hardly increases. If the temperature exceeds 52°C, the reduced coenzyme Q10 crystals may melt during drying.
- the above conditions are not limited.
- the drying may be carried out at °C or higher.
- the heating time for drying is also not particularly limited, but is preferably 4 hours or longer, preferably 10 hours or longer, and more preferably 20 hours or longer.
- the upper limit of the heating time is not particularly limited, but is usually 72 hours or less, preferably 48 hours or less, more preferably 36 hours or less.
- each step in the method of the present embodiment specifically, the seed crystal addition step and the crystal precipitation step described above, the recovery step such as solid-liquid separation and drying, and other subsequent treatment steps, etc.
- a deoxygenated atmosphere can be achieved by replacing the atmosphere with an inert gas, reducing pressure, boiling, or a combination thereof. It is preferable to at least replace the atmosphere with an inert gas, ie use an inert gas atmosphere.
- the inert gas include nitrogen gas, helium gas, argon gas, hydrogen gas, carbon dioxide gas, etc. Nitrogen gas is preferred.
- Form II reduced coenzyme Q10 crystals are contained in the obtained reduced coenzyme Q10 crystals or crystalline solid thereof and the content ratio thereof are measured by, for example, a differential scanning calorimeter (DSC). It is possible to discriminate by DSC.
- Form II reduced coenzyme Q10 crystals show an endothermic peak at around 52 ⁇ 2° C. when measured by DSC at a heating rate of 1° C./min, indicating that Form I reduced coenzyme Q10 The crystal shows an endothermic peak around 48 ⁇ 1° C. under the same conditions.
- Form II reduced coenzyme Q10 crystals are mixed with conventional Form I reduced coenzyme Q10 crystals or a crystalline solid thereof, the presence or absence of the peak near 52 ⁇ 2 ° C. and the endotherm thereof.
- the presence or absence of Form II reduced coenzyme Q10 crystals and their content can be determined from the height of the peak and the ratio of the endothermic amounts.
- the slurry containing Form II reduced coenzyme Q10 crystals has excellent filterability. Therefore, the method for producing Form II-type reduced coenzyme Q10 crystals or the crystalline solid thereof of the present invention can reduce the frequency of cleaning the filtration device and replacing the filtration device, and is excellent in productivity. .
- Form II-type reduced coenzyme Q10 crystals can be obtained through the crystal precipitation step. A solid may be obtained. Therefore, this embodiment encompasses cases where crystals are obtained and where crystalline solids are obtained.
- ⁇ Filterability evaluation method> The slurries obtained in Examples and Comparative Examples are subjected to constant pressure filtration with a filtrate volume of 200 ml and a filtration pressure of 0.1 hPa, the filtration rate is measured, the average filtration specific resistance ( ⁇ av ) is calculated, and the filtration It was used for sex evaluation.
- Form II crystals in reduced coenzyme Q10 crystals The ratio of Form II crystals in the reduced coenzyme Q10 crystals obtained in Examples and Comparative Examples was determined by analyzing the crystals by DSC measurement under the following conditions, and measuring the endothermic peak height (Y difference ) (hereinafter referred to as Form I Y difference) and the height of the endothermic peak (Y difference) of Form II type crystal (hereinafter referred to as Form II Y difference).
- Form II ratio (%) Y difference of Form II / (Y difference of Form I + Y difference of Form II) x 100
- DSC measurement conditions Apparatus: DSC6220 (manufactured by SII Nano Technology)
- Sample container Aluminum pan & cover (SSC000C008) Heating rate: 1°C/min Sample amount: 5 ⁇ 2 mg
- FTU change rate in Examples and Comparative Examples was obtained by measuring the formazin turbidity (FTU) of a mixture of ethanol and reduced coenzyme Q10 with a turbidimeter, and the FTU change rate at time (T) was calculated using the following formula: Calculated by Further, the turbidity meter used in this embodiment was calibrated with a turbidity (FTU) of 9,999 FTU when crystals of reduced coenzyme Q10 were present in the mixed solution at a concentration of 40000 mg/L.
- FTU formazin turbidity
- FTU change rate T (FTU/min) (measured turbidity value T (FTU) - measured turbidity value T-20 (FTU))/20 (min)
- the FTU change rate T means the FTU change rate at time (T)
- the turbidity measurement value T (FTU) means the FTU measurement value at time (T)
- the turbidity measurement value T- 20 (FTU) means the FTU measurement 20 minutes before time T.
- Turbidity meter Backscattered light turbidity sensor (InPro8200, Mettler Toledo Corporation) Measurement range: 0 to 10,000 FTU
- the FTU measurement was performed immediately after the addition of the seed crystal until the FTU reached the upper measurement limit of 10,000, and the FTU change rate was calculated during the period when the FTU was between 1,000 and 10,000.
- the FTU change rate at a certain point T is obtained by calculating the amount of increase in the FTU at the point T from the FTU at the point 20 minutes before (T-20min) and dividing it by 20 minutes. rice field.
- Example 1 After replacing a separable flask with a volume of 3 L with nitrogen, add 144 g of reduced coenzyme Q10 and 1296 g of ethanol with a purity of 99.5% by weight or more (reduced coenzyme Q10 concentration: 10% by weight), and stir with a stirring blade (stirring required The mixture was heated to 50° C. with a power of 0.03 kw/m 3 ) to obtain a uniform reduced coenzyme Q10 solution (QH solution) (1440 g, 1800 ml).
- QH solution uniform reduced coenzyme Q10 solution
- the QH solution at 50°C was cooled to 35.0°C while stirring with a stirring blade (required power for stirring: 0.03 kw/m 3 ).
- To the QH solution (FTU199) cooled to 35.0 ° C. 2.9 g (2.0 wt%) of Form II reduced coenzyme Q10 crystals were added as seed crystals, and precipitation of reduced coenzyme Q10 crystals (crystallization ) was started.
- the QH solution to which the seed crystals are added is hereinafter referred to as "crystallization mixture”.
- the temperature was maintained at 35.0°C for 1 hour, and then cooled from 35.0°C to 32.0°C at a rate of 0.2°C/hr (primary cooling). Thereafter, cooling was performed at 1°C/hr to 25°C, and cooling was performed at 10°C/hr from 25°C to 1°C.
- the formazin turbidity (FTU) of the crystallization mixture was measured with a turbidimeter, and during the entire period from 1,000 to 10,000, The maximum FTU change rate is 32.5 FTU/min, and the FTU change rate is 15.3 to 32.5 FTU/min for 80% or more of the time from 1,000 to 10,000 FTU. was confirmed to be maintained.
- Form II type crystal ratio in the obtained reduced coenzyme Q10 crystals was 100%, and Form I type reduced coenzyme Q10 crystals were not contained.
- the median diameter of the reduced coenzyme Q10 crystal was 115.3 ⁇ m, and ⁇ av was 0.47 ⁇ 10 10 m/kg.
- Example 2 After purging a four-neck flask with a volume of 500 mL with nitrogen, add 33 g of reduced coenzyme Q10 and 295 g of ethanol of 99.5 wt% or more (reduced coenzyme Q10 concentration: 10 wt%), and stir with a stirring blade (stirring required It was heated to 50° C. with a power of 0.007 kw/m 3 ) to obtain a homogeneous QH solution (328 g, 410 ml).
- the QH solution at 50°C was cooled to 36.8°C while stirring with a stirring blade (required power for stirring: 0.007 kw/m 3 ).
- 0.66 g (2.0 wt%) of Form II reduced coenzyme Q10 crystals were added as seed crystals to initiate precipitation (crystallization) of reduced coenzyme Q10 crystals. did.
- the target is to maintain the FTU change rate at around 55.6 FTU/min during the period from 1,000 to 10,000 in the formazin turbidity (FTU) of the crystallization mixture after adding the seed crystals. controlled. After the formazin turbidity reached 10,000 FTU, it was cooled to 25°C at 1°C/hr and from 25°C to 1°C at 10°C/hr. The maximum FTU change rate is 105.2 FTU / min and the minimum is 30.6 FTU / min in the entire period from the formazin turbidity (FTU) to 1,000 to 10,000, the formazin It was confirmed that the FTU change rate was maintained at 81.0 FTU/min or less for 80% or more of the period from 1,000 to 10,000 in turbidity (FTU).
- Form II type crystal ratio in the obtained reduced coenzyme Q10 crystals was 100%, and Form I type reduced coenzyme Q10 crystals were not contained.
- the median diameter of the reduced coenzyme Q10 crystal was 87.6 ⁇ m, and ⁇ av was 0.98 ⁇ 10 10 m/kg.
- Example 3 After purging a four-neck flask with a volume of 500 mL with nitrogen, add 33 g of reduced coenzyme Q10 and 295 g of ethanol of 99.5 wt% or more (reduced coenzyme Q10 concentration: 10 wt%), and stir with a stirring blade (stirring required It was heated to 50° C. with a power of 0.007 kw/m 3 ) to obtain a homogeneous QH solution (328 g, 410 ml).
- the QH solution at 50°C was cooled to 34.5°C while stirring with a stirring blade (required power for stirring: 0.007 kw/m 3 ).
- 0.66 g (2.0 wt%) of Form II reduced coenzyme Q10 crystals were added as seed crystals to initiate precipitation (crystallization) of reduced coenzyme Q10 crystals. did.
- the target is to maintain the FTU change rate at around 33.3 FTU/min during the period from 1,000 to 10,000 in the formazin turbidity (FTU) of the crystallization mixed solution after seed crystal addition. controlled. After the formazin turbidity reached 10,000 FTU, it was cooled to 25°C at 1°C/hr and from 25°C to 1°C at 10°C/hr. The maximum FTU change rate is 41.7 FTU / min and the minimum is 14.4 FTU / min in the entire period from the formazin turbidity (FTU) to 1,000 to 10,000, FTU is It was confirmed that the FTU change rate was maintained between 22.5 and 41.7 FTU/min for 80% or more of the period from 1,000 to 10,000.
- FTU formazin turbidity
- Form II type crystal ratio in the obtained reduced coenzyme Q10 crystal was 100%.
- the median diameter of the reduced coenzyme Q10 crystal was 107.3 ⁇ m, and ⁇ av was 0.48 ⁇ 10 10 m/kg.
- the QH solution at 50°C was cooled to 36.8°C while stirring with a stirring blade (required power for stirring: 0.007 kw/m 3 ).
- 0.6 g (2.0 wt%) of Form II reduced coenzyme Q10 crystals were added as seed crystals to initiate precipitation (crystallization) of reduced coenzyme Q10 crystals. did.
- the set temperature was set with the goal of maintaining the FTU change rate at around 6.9 FTU/min during the period from 1,000 to 10,000 in the formazin turbidity (FTU) of the crystallization mixed solution after seed crystal addition. controlled. After the formazin turbidity reached 10,000 FTU, it was cooled to 25°C at 1°C/hr and from 25°C to 1°C at 10°C/hr. It was confirmed that the FTU change rate was maintained at less than 15 FTU/min for 95% or more of the period from 1,000 to 10,000 for the formazin turbidity (FTU).
- Form II type crystal ratio in the obtained reduced coenzyme Q10 crystals was 100%, and Form I type reduced coenzyme Q10 crystals were not contained.
- the median diameter of the reduced coenzyme Q10 crystal was 68.2 ⁇ m, and ⁇ av was 3.4 ⁇ 10 10 m/kg.
- Table 1 shows the results of Examples and Comparative Examples.
- the slurry obtained in the example (slurry cooled to 1 ° C.) has a clearly lower average filtration specific resistance ( ⁇ av ) and excellent filterability compared to the slurry obtained in the comparative example. .
- ⁇ av average filtration specific resistance
- the period until the formazin turbidity (FTU) becomes 1,000 to 10,000 is It can be seen that when the FTU change rate is maintained within a specific range for 80% or more of the time, the filterability of the slurry containing Form II reduced coenzyme Q10 crystals is excellent. That is, by maintaining the FTU change rate within a specific range, Form II reduced coenzyme Q10 crystals can be efficiently recovered by simple filtration. It can be seen that the productivity of crystals or crystalline solids thereof is excellent.
- a preferred range can be defined by arbitrarily combining the upper and lower limits of the numerical range
- a preferred range can be defined by arbitrarily combining the upper limits of the numerical range
- the lower limit of the numerical range Any combination of values can be used to define a preferred range.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023508902A JP7695994B2 (ja) | 2021-03-26 | 2022-03-04 | FormII型の還元型補酵素Q10結晶又はその結晶性固体の製造方法 |
| US18/281,592 US20240158330A1 (en) | 2021-03-26 | 2022-03-04 | Production method for reduced coenzyme q10 form-ii type crystal or crystalline solid thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021-052652 | 2021-03-26 | ||
| JP2021052652 | 2021-03-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022202214A1 true WO2022202214A1 (ja) | 2022-09-29 |
Family
ID=83396952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2022/009361 Ceased WO2022202214A1 (ja) | 2021-03-26 | 2022-03-04 | FormII型の還元型補酵素Q10結晶又はその結晶性固体の製造方法 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20240158330A1 (https=) |
| JP (1) | JP7695994B2 (https=) |
| WO (1) | WO2022202214A1 (https=) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012176842A1 (ja) * | 2011-06-24 | 2012-12-27 | 株式会社カネカ | 安定性に優れた還元型補酵素q10結晶 |
| WO2020045571A1 (ja) * | 2018-08-30 | 2020-03-05 | 株式会社カネカ | 安定性に優れた還元型補酵素q10結晶の製造方法 |
| WO2020067275A1 (ja) * | 2018-09-28 | 2020-04-02 | 株式会社カネカ | 安定性に優れた還元型補酵素q10結晶の製造方法 |
| WO2021161807A1 (ja) * | 2020-02-12 | 2021-08-19 | 株式会社カネカ | FormII型の還元型補酵素Q10結晶の製造方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI237018B (en) * | 2001-07-13 | 2005-08-01 | Kaneka Corp | Method of producing reduced coenzyme Q10 crystals |
| TWI329510B (en) * | 2001-10-10 | 2010-09-01 | Kaneka Corp | Method of stabilizing reduced coenzyme q10 |
| JP2015131766A (ja) * | 2012-04-27 | 2015-07-23 | 株式会社カネカ | 還元型補酵素q10の製造方法 |
-
2022
- 2022-03-04 WO PCT/JP2022/009361 patent/WO2022202214A1/ja not_active Ceased
- 2022-03-04 JP JP2023508902A patent/JP7695994B2/ja active Active
- 2022-03-04 US US18/281,592 patent/US20240158330A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012176842A1 (ja) * | 2011-06-24 | 2012-12-27 | 株式会社カネカ | 安定性に優れた還元型補酵素q10結晶 |
| WO2020045571A1 (ja) * | 2018-08-30 | 2020-03-05 | 株式会社カネカ | 安定性に優れた還元型補酵素q10結晶の製造方法 |
| WO2020067275A1 (ja) * | 2018-09-28 | 2020-04-02 | 株式会社カネカ | 安定性に優れた還元型補酵素q10結晶の製造方法 |
| WO2021161807A1 (ja) * | 2020-02-12 | 2021-08-19 | 株式会社カネカ | FormII型の還元型補酵素Q10結晶の製造方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7695994B2 (ja) | 2025-06-19 |
| JPWO2022202214A1 (https=) | 2022-09-29 |
| US20240158330A1 (en) | 2024-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230339836A1 (en) | Method for producing reduced coenzyme q10 form ii crystals | |
| EP4077293B1 (en) | Thermal treatment of purified 2,5-furandicarboxylic acid resulting carboxylic acid composition | |
| CN111393446A (zh) | 3,5-二取代的苯炔基化合物晶体 | |
| JP3796763B2 (ja) | 結晶形2,2−ビス(3,5−ジブロモ−4−ジブロモプロポキシフェニル)プロパン及びその製造方法 | |
| EP1225174B2 (en) | Anhydrous mirtazapine crystals and process for the production thereof | |
| Di Martino et al. | Influence of solvent and crystallization method on the crystal habit of metronidazole | |
| WO2022202214A1 (ja) | FormII型の還元型補酵素Q10結晶又はその結晶性固体の製造方法 | |
| JP7695993B2 (ja) | FormII型の還元型補酵素Q10結晶又はその結晶性固体の製造方法 | |
| WO2022202215A1 (ja) | FormII型の還元型補酵素Q10結晶又はその結晶性固体の製造方法及び晶析装置 | |
| JPH0948754A (ja) | ジクミルペルオキシドの精製方法 | |
| EP1537049B1 (fr) | Procede de fabrication de poudres cristalline d oxyde de lit hium et de vanadium | |
| TWI496789B (zh) | 表柔比星(epirubicin)鹽酸鹽之結晶 | |
| US8232389B2 (en) | Method for crystallization of azetidinonecarboxylic acid | |
| CN103819487B (zh) | 一种利福平晶体及其制备方法 | |
| EP4317163A1 (en) | Method for preparing biotin, l-lysine salt of biotin, and method for preparing same | |
| JP4849374B2 (ja) | (±)2−(ジメチルアミノ)−1−{〔O−(m−メトキシフェネチル)フェノキシ〕メチル}エチル水素サクシナート塩酸塩のI形結晶とII形結晶の混晶の製造法 | |
| JP6382660B2 (ja) | オルメサルタンメドキソミルの製造方法 | |
| WO2019155922A1 (ja) | アジルサルタンa型結晶の製造方法 | |
| JP2013213032A (ja) | (2rs)−1−ジメチルアミノ−3−{2−[2−(3−メトキシフェニル)エチル]フェノキシ}プロパン−2−イルコハク酸水素塩酸塩の工業的製造方法 | |
| KR102650450B1 (ko) | Cyclic-di-AMP 나트륨염 결정 | |
| JP5448588B2 (ja) | L−カルノシンの精製方法 | |
| CN118791433A (zh) | 一种伊卢多啉中间体的草酸盐晶型及其制备方法 | |
| WO2024204380A1 (ja) | 還元型補酵素q10の結晶及び製剤 | |
| CN120987746A (zh) | 一种异香兰素的纯化方法 | |
| CN115785446A (zh) | 一种砜类聚合物的纯化方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22775010 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2023508902 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 18281592 Country of ref document: US |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 22775010 Country of ref document: EP Kind code of ref document: A1 |